ALZN — Alzamend Neuro, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1677077 ·
Last close
$1.31
Market Cap
$6.28M
52W High
$1.38
52W Low
$1.00
ADV30
235,580
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -2,870,877 | -2,869,949 | 2,079,363 | 710,689 | 1,346,152 |
| Jan 2026 | 0 | — | -2,197,654 | -2,198,991 | 4,041,833 | 2,713,139 | 1,857,328 |
| Oct 2025 | 0 | — | -998,109 | -1,000,758 | 5,091,684 | 4,449,433 | 717,488 |
| Jul 2025 | 0 | — | -2,700,201 | -2,702,684 | 6,326,751 | 5,620,872 | 983,311 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,067,813
Investing CF
$0
Financing CF
$4,829,844
CapEx
$-210,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.91
As of
2026-07-26
Balance + Analyst (yfinance extras)
Retained Earnings
$-67,307,643
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-8,765,763
Pretax Income TTM
$-8,772,382
Interest Exp TTM
$6,619
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | -8,766,841 | -8,772,382 | 2,079,363 | 1,346,152 | — | -8,067,813 |
| Apr 2025 | 0 | -4,496,824 | -4,514,853 | 4,602,983 | 634,761 | — | -6,568,186 |
| Apr 2024 | 0 | -9,937,645 | -9,947,746 | 631,588 | 3,225,773 | — | -8,269,993 |
| Apr 2023 | 0 | -14,870,466 | -14,878,167 | 5,915,625 | 2,870,122 | — | -8,923,152 |
| Apr 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | $6.32M | $1.57 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.23M | $2.01 | — |
| PULM | Pulmatrix, Inc. | $6.35M | $1.74 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.19M | $1.44 | — |
| KAPA | Kairos Pharma, LTD. | $6.55M | $0.31 | — |
News headlines (Yahoo Finance, 1h cache)
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
2026-04-07 12:00 · Yahoo
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured
2026-03-26 12:00 · Yahoo
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
2026-03-16 12:00 · Yahoo
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
2026-01-26 14:40 · Yahoo
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
2025-11-20 12:50 · Yahoo
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
2025-11-19 13:00 · Yahoo
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
2025-11-19 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.